- Conditions
- Neoplasms
- Interventions
- Gemcitabine, BAY80-6946, Cisplatin, NaCl, BAY80-6964 fixed dose
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 2,486
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
- Interventions
- CLSP-5282
- Drug
- Lead sponsor
- Clasp Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
- Conditions
- Refractory Malignancy
- Interventions
- Capecitabine and Sorafenib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
- Conditions
- Cancer
- Interventions
- capecitabine, cisplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI4736, tremelimumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Duarte, California • La Jolla, California + 23 more
- Conditions
- Cancer
- Interventions
- PTC596
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee
- Conditions
- Neoplasms, Tumor
- Interventions
- IMC-TR1
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • Houston, Texas • San Antonio, Texas
- Conditions
- Adult Solid Neoplasm
- Interventions
- Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ixabepilone, lapatinib ditosylate
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 1 more
- Conditions
- Neoplasms
- Interventions
- RO7673396
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Duarte, California • Aurora, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors
- Interventions
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Pasadena, California + 10 more
- Conditions
- Urethral Neoplasms, Neoplasms, Urethral, Cancer of the Urethra, Urethral Cancer
- Interventions
- Gemcitabine, Carboplatin, Lenalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
- Interventions
- TUB-030
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more
- Conditions
- Neoplasms
- Interventions
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms, Lung Neoplasms
- Interventions
- SN2310 Injectable Emulsion
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Malignant Solid Tumor
- Interventions
- SAR439459, Cemiplimab REGN2810
- Biological · Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Fairway, Kansas • Boston, Massachusetts • Durham, North Carolina + 2 more
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Interventions
- PF-08046049
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Pasadena, California • San Francisco, California + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma
- Interventions
- LBH589
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Augusta, Georgia • Chicago, Illinois + 1 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, mitomycin C
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer, Tumors, Neoplasm, Malignancy
- Interventions
- BMS-986226, Nivolumab, Ipilimumab, Tetanus Vaccine
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 2 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- DAY301
- Drug
- Lead sponsor
- Day One Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- New Haven, Connecticut • Sarasota, Florida • Avon, Indiana + 6 more
- Conditions
- Advanced Solid Malignancies
- Interventions
- MLN0128
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 11 more
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
- Interventions
- MGC028
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more